Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death

Vanesa Martín; Guillermo García-Santos; Jezabel Rodriguez-Blanco; Sara Casado-Zapico; Ana Sanchez-Sanchez; Isaac Antolín; Maria Medina; Carmen Rodriguez

doi:10.1016/j.canlet.2009.06.016

Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death

Vanesa Martín, Guillermo García-Santos, Jezabel Rodriguez-Blanco, Sara Casado-Zapico, Ana Sanchez-Sanchez, Isaac Antolín, Maria Medina, Carmen Rodriguez

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Abstract

Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels.

Original language	English (US)
Pages (from-to)	216-223
Number of pages	8
Journal	Cancer Letters
Volume	287
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2009.06.016
State	Published - Jan 28 2010
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Keywords

Apoptosis
Death receptors
Glioma
Melatonin
TRAIL

Access to Document

10.1016/j.canlet.2009.06.016

Cite this

@article{348be8233fe047f4ab9c152a1f1629a3,

title = "Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death",

abstract = "Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels.",

keywords = "Apoptosis, Death receptors, Glioma, Melatonin, TRAIL",

author = "Vanesa Mart{\'i}n and Guillermo Garc{\'i}a-Santos and Jezabel Rodriguez-Blanco and Sara Casado-Zapico and Ana Sanchez-Sanchez and Isaac Antol{\'i}n and Maria Medina and Carmen Rodriguez",

year = "2010",

month = jan,

day = "28",

doi = "10.1016/j.canlet.2009.06.016",

language = "English (US)",

volume = "287",

pages = "216--223",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death

AU - Martín, Vanesa

AU - García-Santos, Guillermo

AU - Rodriguez-Blanco, Jezabel

AU - Casado-Zapico, Sara

AU - Sanchez-Sanchez, Ana

AU - Antolín, Isaac

AU - Medina, Maria

AU - Rodriguez, Carmen

PY - 2010/1/28

Y1 - 2010/1/28

N2 - Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels.

AB - Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels.

KW - Apoptosis

KW - Death receptors

KW - Glioma

KW - Melatonin

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=72949118848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949118848&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2009.06.016

DO - 10.1016/j.canlet.2009.06.016

M3 - Article

C2 - 19632770

AN - SCOPUS:72949118848

SN - 0304-3835

VL - 287

SP - 216

EP - 223

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this